Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL235848 | 0.91 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1SLC6A3GAAMAPT | |
| SCHEMBL232172 | 0.83 | TPMT (0.32) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL8834132 | 0.76 | NPSR1 (0.34) | SMN1; SMN2ALDH1A1SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL30770833 | 0.75 | — | — | |
| SCHEMBL5607802 | 0.75 | SLC6A3 (0.44) | SMN1; SMN2ALDH1A1SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL3295918 | 0.74 | KDM4E (0.56) | SMN1; SMN2ALDH1A1SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL9255427 | 0.73 | TDP1 (0.32) | TDP1 | |
| SCHEMBL28273825 | 0.72 | SLC6A2 (0.35) | SMN1; SMN2ALDH1A1SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL2371417 | 0.71 | SLC6A3 (0.54) | SLC6A2SLC6A3SLC6A4ACHE | |
| SCHEMBL9561660 | 0.71 | SLC6A3 (0.50) | SLC6A2SLC6A3SLC6A4ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673890-B2 | 2,3-dihydro-1H-isoindol-1-imine derivatives useful as thrombin PAR-1 receptor antagonist | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-18 | — | — | US | disclosed |
| US-20110105490-A1 | 2,3-DIHYDRO-1H-ISOINDOL-1-IMINE DERIVATIVES USEFUL AS THROMBIN PAR-1 RECEPTOR ANTAGONIST | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105490-A1 | 2,3-DIHYDRO-1H-ISOINDOL-1-IMINE DERIVATIVES USEFUL AS THROMBIN PAR-1 RECEPTOR ANTAGONIST | F2R, F2RL1, F2RL3 | SMN1; SMN2 3382/4885ALDH1A1 1921/4885SLC6A2 4434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.